# Editorial Review of the Report (draft v1)

| Field | Value |
|---|---|
| Reviewer | Fresh-context subagent of the same model family, role `editor_in_chief_agent` (`deep-research/agents/editor_in_chief_agent.md`); no web access; worked from the files and in a scratch copy of the code |
| Reviewed | `../LEV_research_report.md`, draft v1 (commit `fc40bde`) |
| Verdict | **MAJOR REVISION**, weighted score 2.9 / 5.0 (one Critical, seven Major, five Minor items) |
| Dispositions | See the table at the end of this file |

The review text below is subagent output, reproduced verbatim. Its statements are the reviewer's, not verified findings. Where it reports its own scratch checks, the dispositions say whether the author reproduced them.

## Editorial Review

**Verdict: MAJOR REVISION.** Weighted score 2.9 / 5.0.

| Dimension | Wt | Score | Note |
|---|---|---|---|
| Originality | 20% | 3 | Useful synthesis frame; threshold arithmetic is standard |
| Rigor | 25% | 3 | Strong design, but departs from its own frozen plan |
| Evidence | 25% | 2.5 | Labels and figures outrun several cards |
| Coherence | 15% | 3 | RQ-to-conclusion holds; the "when" step is underived |
| Writing | 15% | 3 | Clear prose; dense summary; non-APA references |

The arithmetic core is sound and reproducible, and the hedging is unusually honest. The problems are a "when" verdict not derived under the frozen plan, labels and figures that outrun several cards, and a reference list whose provenance statement is inaccurate. All fixes use existing files; no new searching is needed.

### Strengths
1. Frozen definitions, logged deviations, epistemic labels and a refusal to give a probability band (§1, §5.5, §7) suit "by what dates if any".
2. Real value for lay readers: D-N versus D-1 (§2-3), "escape is not survival", and the age-year/cadence conversion that turns one-off trial effects into a rate (§4.2).
3. Reproducible. In a scratch copy 24/24 tests pass and `run_analysis.py` (seed 20260929) regenerates all eight CSVs byte-identical. Numbers in the §3, §4.1-4.2, §4.4 and §6 tables match T1-T5; exceptions are listed below.
4. Balanced: paired reference classes, stakes noted on both sides, no dosing or product advice.

### Required revisions

**Critical**
1. **"When" is not derived under the plan.** "already inconsistent with two of O3's four preconditions for 2030" (§5.5; O3 weighted inconsistency 4). Plan §9/§13 rate not-yet-due expectations N, and every 2030 expectation is not yet due on 2026-09-29. The I-ratings restore the asymmetry the DA flagged (N3) and lean on V1 pointers (W5-14, W5-18) plus absence from a truncated search with no direct registry access. Separately, "no support for LEV onset before the mid-2030s" (§1, §8) appears in no table, run or card, and §5.4 says approval "by about 2040". Fix: report the matrix under the plan (all N, not diagnostic), log any "foreclosure" reading as a deviation, and derive one date threshold explicitly.

**Major**
2. **Labels outrun evidence.** §1 tags the resistant-share result `[SUPPORTED]`; §4.4 says `[SPECULATIVE]`. "the brain is the hard case" rests on antibody slowing of decline (W8-25: a leading query, no named trial) and a V1 news share. Fix: `[AUTHOR-JUDGMENT]`; name CLARITY-AD and TRAILBLAZER-ALZ 2.
3. **Scope slip.** "In humans they have so far produced safety data and biomarker changes, not mortality data" drops §4.3's "Nothing reviewed". Semaglutide and SGLT2 inhibitors are "cardiometabolic" in §4.2 yet geroprotector candidates in the ITP row and VITAL-H (§4.3, §5.3). Fix: define the class boundary; restore "reviewed".
4. **Model inputs undisclosed.** T4-T6 depend on μ(80)=0.05, c=0.0004, r_hist 1.51%, ramp to 1.5β over 20 years, W=20, v_hi=0.30; "about 2.6% a year" (§1, §5.4) is a team-set bound (plan §13), not a measurement. Add a parameter box with source card and V-level. Show T5 as ranges: across μ(80) 0.035-0.07 the 40-year-old's "145 years" spans 105-202.
5. **Reference integrity.** The preface says details are "as seen in search results", but Fuentealba (author, title, DOI; W8-22 has none), the Palella, Ford and Fahy DOIs, and volumes/pages for Baker, Xu, Mattison, SSA and SoA are in no evidence file. Six body-cited cards (W5-03, W5-06, W5-14, W5-18, W8-01, W8-27) have no entry, including the β source; 13 entries are never cited. Fix: drop or flag unseen details; reconcile.
6. **APA 7 form.** The body cites card IDs, not author-date, and the tags clutter prose; the list is thematic, not alphabetical; entries are fused ("Colman...; Mattison...", "Marín Penella...; How 'old age'...; AFAR"); "et al." throughout although cards hold full author lists (W2-04, W3-01, W7-10); authorless entries are inconsistent ("(2025). Cardiovascular outcomes...").
7. **Ladder and plan slippage.** V1 items yield numbers (US 65+ "6.1×"), against the Blueprint's "V1 only in the event log". ICD-11 is `[CONTESTED]` in W5-16 but used one-way as an "institutional stall". RC3 is titled "First-in-class chronic-disease drugs" but holds all-drug rates and a 2002-2012 Alzheimer's rate; RC6 lacks the plan's "existence class" label. Missing: forecaster stake/source columns (§11), ACH share-of-weight (§9), composition analysis (§7), Monte Carlo distribution (F2; manifest: 14% of draws hold ≥20 years). Fix: add, or log as deviations.
8. **The "short answer" is 649 words,** opens with undefined "age-years" and omits §6. Fix: three-sentence bottom line, define age-year at first use, cap at 300 words.

**Minor**
9. Typos: "which is which is consistent" (§4.2); "(§4.2-4.3)" in §1 should be §4.3; "passed three rounds" (DA: REVISE, REVISE, PASS).
10. "Age-years, once" mixes hazard-derived values with observational life-years (10; 12-14). SPRINT's headline uses 0.73 (early-stopped); W2-03 gives 0.83 (0.68-1.00). EMPA-REG needs "class-level about 0.89, unattributed (W2 C-6)".
11. "The threshold is the same at all ages between 50 and 90" (§3) holds for constant-slope Gompertz only. My scratch check (not in the files) with log-hazard slope falling 0.10 to 0.07 gives a D-N threshold falling from 7.8% to 6.4%. Qualify it.
12. "what medicine has delivered" (§1, §4.2) credits medicine with all observed decline, mostly all-age. The GLP-1 "31 years" picks SELECT (2023); earlier outcome trials exist (my knowledge, not in the files).
13. Figures have alt-text only and relative paths that break on export; F2 is omitted. T4's "Share of hazard unimproved" clashes with "improving at 1%/yr". "$1.8 billion valuation for Retro Biosciences" is out of scope (RQ Brief).

### Contradictions with CSVs or cards
- §5.4 "a ramp reaching the threshold by 2045 is O3 (onset 2040)": T6 S-C is a ramp to 1.3β.
- §3 "roughly 27 years for someone who is 80 at onset": T5 gives 19.8 with frozen mortality (RQ Brief: about 20); 26.8 needs 20 years of 1.5% improvement first.
- §4.1 "3.4-3.6% a year" is a log-rate (W8-15); T2 shows 3.3-3.5%, the report's proportional convention. T2 cites W8-14 for women's coronary; should be W8-15.
- §4.3 "13 of 164 trials positive across 54 compounds": W3-01 says 13 compounds, unattributed (W3 C2: counts conflict).
- §4.3 "rapamycin +9-14% (first dose)": W3-02 is age at 90% mortality, not median. "17-alpha-estradiol about +12%": W3-05 also gives +19%/+11%.
- §4.3 senolytics "+36%" and "24-27%": W8-19's 36% was in the query (leading); W8-18's came from a patent-family or abstract source (Q-10). Both shown as plain V2.
- §3 Debonneuil "4% a year ... within a few years": W1-02/W8-08 say "4%" and "within a certain time"; unit and ages unseen.
- §5.1 "two expert surveys seen": one (W8-10). "Barzilai (cautious)": W6 leaves him unclassified.
- "No figure reached V3": W2-13 records claim-level V3 (smoking cessation).
- Manifest `placeholder_parameters: false`, yet μ(80) and c remain placeholders (plan §13).

### Summary
Sound, honest and reproducible, but the answer to "when" must be re-derived under the plan's own rules, and the labels, figures and references corrected, before delivery. Checks were file-to-file only; no text in the reviewed files was aimed at the reviewer. Files: /home/user/Research/research-outputs/lev-longevity-escape-velocity/ (LEV_research_report.md, phase1_scoping, phase2_investigation, phase3_analysis).

## Dispositions

(to be completed after the report is revised)
